Email Updates

Search form

You are here

Successful trial of quadrivalent mosaic HIV vaccine paves way for larger study in Southern Africa

Include in
Media Coverage

A quadrivalent mosaic HIV vaccine induced greater immune responses on a variety of assays and against several HIV clades than its trivalent equivalent, Daniel J. Stieh, Ph.D., of Janssen Vaccines & Prevention BV reported at the HIVR4P conference in Madrid, Spain. This quadrivalent version will be used in future vaccine studies, he added.

October 24, 2018
The BodyPro